SG11202006905YA - Fc variants with enhanced binding to fcrn and prolonged half-life - Google Patents
Fc variants with enhanced binding to fcrn and prolonged half-lifeInfo
- Publication number
- SG11202006905YA SG11202006905YA SG11202006905YA SG11202006905YA SG11202006905YA SG 11202006905Y A SG11202006905Y A SG 11202006905YA SG 11202006905Y A SG11202006905Y A SG 11202006905YA SG 11202006905Y A SG11202006905Y A SG 11202006905YA SG 11202006905Y A SG11202006905Y A SG 11202006905YA
- Authority
- SG
- Singapore
- Prior art keywords
- fcrn
- variants
- life
- enhanced binding
- prolonged half
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006905YA true SG11202006905YA (en) | 2020-08-28 |
Family
ID=65520379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006905YA SG11202006905YA (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (en) |
| EP (1) | EP3743441A1 (en) |
| JP (2) | JP7399880B2 (en) |
| KR (1) | KR20200115568A (en) |
| CN (1) | CN111788221A (en) |
| AU (1) | AU2019212638A1 (en) |
| BR (1) | BR112020015006A2 (en) |
| CA (1) | CA3089602A1 (en) |
| CO (1) | CO2020010269A2 (en) |
| IL (1) | IL276286A (en) |
| MX (1) | MX2020007882A (en) |
| PH (1) | PH12020551134A1 (en) |
| SG (1) | SG11202006905YA (en) |
| TW (1) | TW201940512A (en) |
| WO (1) | WO2019147973A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022542884A (en) * | 2019-07-25 | 2022-10-07 | ジェンザイム・コーポレーション | Methods of treating antibody-mediated disorders with FCRN antagonists |
| EP4149969A1 (en) * | 2020-05-11 | 2023-03-22 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| WO2022090469A2 (en) * | 2020-10-29 | 2022-05-05 | Formycon Ag | Ace2 fusion proteins and uses thereof |
| IL308733A (en) | 2021-05-27 | 2024-01-01 | Sanofi Sa | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY |
| CA3227716A1 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| ES2694002T3 (en) * | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
| EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| CN1871259A (en) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | Improved antibodies having altered effector function and methods for making the same |
| KR20070057839A (en) * | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | Polypeptide variants with altered effector function |
| DK1817340T3 (en) | 2004-11-12 | 2012-08-13 | Xencor Inc | FC VARIATIONS WITH CHANGED BINDING TO FCRN |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8775090B2 (en) * | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| BR112012015740B1 (en) * | 2009-12-23 | 2020-09-29 | Synimmune Gmbh | ANTI-FLT3 ANTIBODY, ITS USE, AS WELL AS COMPOSITION UNDERSTANDING THE REFERRED ANTIBODY AND NUCLEIC ACID MOLECULE |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI743461B (en) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (en) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| EP2992010B1 (en) * | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| SI3215528T1 (en) * | 2014-11-06 | 2019-11-29 | Hoffmann La Roche | Fc-region variants with modified fcrn-binding and methods of use |
| RU2017120358A (en) | 2014-11-10 | 2018-12-13 | Ф.Хоффманн-Ля Рош Аг | ANTI-IL-1-BETA ANTIBODIES AND WAYS OF THEIR APPLICATION |
-
2019
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/en unknown
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/en active Active
- 2019-01-25 AU AU2019212638A patent/AU2019212638A1/en active Pending
- 2019-01-25 CN CN201980015900.4A patent/CN111788221A/en active Pending
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/en unknown
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en unknown
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 TW TW108102958A patent/TW201940512A/en unknown
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 KR KR1020207024432A patent/KR20200115568A/en not_active Application Discontinuation
-
2020
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-07-26 IL IL276286A patent/IL276286A/en unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/en unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3089602A1 (en) | 2019-08-01 |
| AU2019212638A1 (en) | 2020-09-17 |
| RU2020128177A (en) | 2022-02-28 |
| PH12020551134A1 (en) | 2021-05-31 |
| CO2020010269A2 (en) | 2020-12-10 |
| BR112020015006A2 (en) | 2020-12-29 |
| JP7399880B2 (en) | 2023-12-18 |
| JP2024026255A (en) | 2024-02-28 |
| JP2021511830A (en) | 2021-05-13 |
| WO2019147973A1 (en) | 2019-08-01 |
| TW201940512A (en) | 2019-10-16 |
| EP3743441A1 (en) | 2020-12-02 |
| US20190263934A1 (en) | 2019-08-29 |
| CN111788221A (en) | 2020-10-16 |
| IL276286A (en) | 2020-09-30 |
| KR20200115568A (en) | 2020-10-07 |
| MX2020007882A (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276286A (en) | Fc variants with enhanced binding to fcrn and prolonged half-life | |
| IL263118A (en) | Tagmentation using immobilized transposomes with linkers | |
| IL276537A (en) | Antibodies binding to gprc5d | |
| IL274371A (en) | Molecules that bind to cd137 and psma | |
| HK1252791A1 (en) | Binding molecules with modified j-chain | |
| IL240606B (en) | Fcrn binding polypeptide comprising an fcrn binding motif (bm) and various aspects related thereto | |
| GB2549632B (en) | Fusion protein comprising three binding domains to 5T4 and CD3 | |
| HK1217502A1 (en) | Il-11r binding proteins and uses thereof il-11r | |
| ZA201906813B (en) | Antibody binding specifically to muc1 and use thereof | |
| ZA202003612B (en) | Engineered immunoglobulins with altered fcrn binding | |
| ZA201905341B (en) | Antibodies specifically binding to human il-1r7 | |
| IL266516A (en) | Antibody binding specifically to cd66c and use thereof | |
| HK1254356A1 (en) | Antibodies that bind to sortilin and inhibit the binding of progranulin | |
| HK1221957A1 (en) | Immunoglobulin fc conjugate maintaining fcrn binding strength fcrn fc | |
| EP3606963C0 (en) | Antibodies binding to steap-1 | |
| EP3247746A4 (en) | Acrylic elastomeric resin composition and file prepared using the same | |
| EP3444279C0 (en) | Antibody having improved stability and specifically binding to her2 | |
| PL3081609T3 (en) | Bituminous adhesive binder and use thereof | |
| GB2574206B (en) | Briquettes | |
| PL3362480T3 (en) | Antibody specifically binding to erbb3 and use thereof | |
| GB201915485D0 (en) | Improvements in or relaing to cognitive function | |
| GB2577503B (en) | Improvements in or relating to lantern roofs | |
| KR102248839B9 (en) | Dna dna aptamer specifically binding to lithium and using the same | |
| ZA202001042B (en) | Antibody specifically binding to pauf protein, and use thereof | |
| GB201820128D0 (en) | Improvements to user interaction system |